Pegteograstim may be effective for reducing chemotherapy-induced neutropenia
the ONA take:
Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer undergoing myelosuppressive chemotherapy, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.
For the phase 2/3 study, researchers sought to evaluate the efficacy and safety of pegteograstim, a new formulation of pegylated granulocyte-colony-stimulating factor (G-CSF), compared with pegfilgrastim in preventing febrile neutropenia.
In the phase 3 portion, researchers enrolled 117 patients with breast cancer who were undergoing treatment with docetaxel plus doxorubicin or docetaxel plus doxorubicin and cyclophosphamide.
Patients were randomly assigned to receive pegteofilgrastim 6.0 mg subcutaneously on day 2 of chemotherapy or pegfilgrastim 6.0 mg subcutaneously.
Results showed that the efficacy of pegteograstim was noninferior to that of pegfilgrastim in the duration of grade 4 neutropenia during cycle 1 of chemotherapy.
Furthermore, the time to absolute neutrophil count recovery was significantly shorter with pegteograstim compared with pegfilgrastim.
In regard to safety, treatment-related adverse events did not differ significantly between the two treatment arms.
Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis
- Intermediate Oncotype DX Scores Prognostic of OS in Early-stage Breast Cancer
- Colorectal Cancer and Dietary Fiber: Source Is More Important Than Amount
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
- Exercise May Mitigate Cardiotoxicity Associated With Doxorubicin Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|